# FertilAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fertilai

- Industry: Healthcare IT
- Headquarters: Giv`atayim, Israel
- Website: www.fertilai.com
- Total disclosed funding: $4.5M
- Latest round: Seed (Nov 20, 2024)
- Investors on record: 2

## About

Founded in 2021 and based in Israel, FertilAI Ltd. supports fertility treatment via its AI-driven platform. In November 2024, FertilAI raised USD 4.5 mn in venture funding, co-led by Longevity Venture Partners and RedSeed Ventures. Rohi Hourvitz is leading the firm as CEO as of 2024.

FertilAI offers an AI-driven platform designed to facilitate the fertility treatment process for healthcare providers and patients alike. The core product, Fertilane, was developed in collaboration with reproductive endocrinology and infertility specialists, integrating artificial intelligence to optimize clinical outcomes. The platform supports various fertility treatments, including ovulation tracking, intrauterine insemination (IUI), and advanced treatments such as in vitro fertilization (IVF). It is aimed at primary care physicians, obstetricians, gynecologists, and reproductive endocrinologists, supporting patient care throughout the fertility journey. The services are marketed primarily in North America and Europe, catering to fertility clinics and individual patients seeking assistance with fertility issues. 

FertilAI generates revenue through a subscription-based model for its platform, which includes distinct services tailored for both healthcare providers and patients. Revenue comes from monthly or annual subscriptions from clinics using the Fertilane platform for fertility treatment planning and patient management. 

FertilAI plans to leverage its recent funding of USD 4.5 mn raised in November 2024 to support workforce growth and expansion initiatives. The company aims to launch new products designed to enhance user experience and treatment outcomes, with specific release dates to be announced. Additionally, FertilAI is targeting expansion into new markets, particularly in North America and Europe, with plans to enter additional regions by 2025.

## Funding rounds

- Seed, Nov 20, 2024, $4.5M — RedSeed Ventures, Longevity Venture Partners

## Investors

- RedSeed Ventures (https://capitalatlas.ai/funds/redseed-ventures) — Seed
- Longevity Venture Partners (https://capitalatlas.ai/funds/longevity-venture-partners) — Seed